Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Insights into PCSK9, low-density lipoprotein receptor, and low-density lipoprotein cholesterol metabolism: of mice and man.

Stein EA, Raal FJ.

Circulation. 2013 Jun 18;127(24):2372-4. doi: 10.1161/CIRCULATIONAHA.113.003360. Epub 2013 May 20. No abstract available.

2.

Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation.

Tavori H, Fan D, Blakemore JL, Yancey PG, Ding L, Linton MF, Fazio S.

Circulation. 2013 Jun 18;127(24):2403-13. doi: 10.1161/CIRCULATIONAHA.113.001592. Epub 2013 May 20.

3.

Effect of Porphyromonas gingivalis infection on post-transcriptional regulation of the low-density lipoprotein receptor in mice.

Miyazawa H, Tabeta K, Miyauchi S, Aoki-Nonaka Y, Domon H, Honda T, Nakajima T, Yamazaki K.

Lipids Health Dis. 2012 Sep 19;11:121. doi: 10.1186/1476-511X-11-121.

4.
5.

Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.

Sasaki M, Terao Y, Ayaori M, Uto-Kondo H, Iizuka M, Yogo M, Hagisawa K, Takiguchi S, Yakushiji E, Nakaya K, Ogura M, Komatsu T, Ikewaki K.

Arterioscler Thromb Vasc Biol. 2014 Jun;34(6):1171-8. doi: 10.1161/ATVBAHA.113.302670. Epub 2014 Mar 27.

6.

Plasma lipoprotein-associated phospholipase A2 is inversely correlated with proprotein convertase subtilisin-kexin type 9.

Constantinides A, Kappelle PJ, Lambert G, Dullaart RP.

Arch Med Res. 2012 Jan;43(1):11-4. doi: 10.1016/j.arcmed.2012.01.001. Epub 2012 Jan 31.

PMID:
22300679
7.

Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation.

Kosenko T, Golder M, Leblond G, Weng W, Lagace TA.

J Biol Chem. 2013 Mar 22;288(12):8279-88. doi: 10.1074/jbc.M112.421370. Epub 2013 Feb 11.

8.

Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.

Zaid A, Roubtsova A, Essalmani R, Marcinkiewicz J, Chamberland A, Hamelin J, Tremblay M, Jacques H, Jin W, Davignon J, Seidah NG, Prat A.

Hepatology. 2008 Aug;48(2):646-54. doi: 10.1002/hep.22354.

PMID:
18666258
9.

Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk.

Guardiola M, Plana N, Ibarretxe D, Cabré A, González M, Ribalta J, Masana L.

Clin Sci (Lond). 2015 Jun;128(12):877-82. doi: 10.1042/CS20140832.

PMID:
25649668
10.

PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study.

Saavedra YG, Dufour R, Davignon J, Baass A.

Arterioscler Thromb Vasc Biol. 2014 Dec;34(12):2700-5. doi: 10.1161/ATVBAHA.114.304406. Epub 2014 Oct 2.

11.

Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study.

Jin K, Park BS, Kim YW, Vaziri ND.

Am J Kidney Dis. 2014 Apr;63(4):584-9. doi: 10.1053/j.ajkd.2013.10.042. Epub 2013 Dec 4.

12.

Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor.

Sun H, Samarghandi A, Zhang N, Yao Z, Xiong M, Teng BB.

Arterioscler Thromb Vasc Biol. 2012 Jul;32(7):1585-95. doi: 10.1161/ATVBAHA.112.250043. Epub 2012 May 10.

13.

PCSK9 and lipid lowering drugs.

Guo YL, Zhang W, Li JJ.

Clin Chim Acta. 2014 Nov 1;437:66-71. doi: 10.1016/j.cca.2014.07.008. Epub 2014 Jul 15. Review.

PMID:
25036764
14.

Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia.

Brouwers MC, Konrad RJ, van Himbergen TM, Isaacs A, Otokozawa S, Troutt JS, Schaefer EJ, van Greevenbroek MM, Stalenhoef AF, de Graaf J.

Nutr Metab Cardiovasc Dis. 2013 Nov;23(11):1115-21. doi: 10.1016/j.numecd.2012.11.008. Epub 2013 Jan 18.

PMID:
23333725
15.

ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.

Li S, Xu RX, Guo YL, Zhang Y, Zhu CG, Sun J, Li JJ.

Nutr Metab Cardiovasc Dis. 2015 Apr;25(4):411-7. doi: 10.1016/j.numecd.2014.10.015. Epub 2014 Nov 5.

PMID:
25466598
16.

Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels.

Lipari MT, Li W, Moran P, Kong-Beltran M, Sai T, Lai J, Lin SJ, Kolumam G, Zavala-Solorio J, Izrael-Tomasevic A, Arnott D, Wang J, Peterson AS, Kirchhofer D.

J Biol Chem. 2012 Dec 21;287(52):43482-91. doi: 10.1074/jbc.M112.380618. Epub 2012 Nov 7.

17.

Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates.

Liang H, Chaparro-Riggers J, Strop P, Geng T, Sutton JE, Tsai D, Bai L, Abdiche Y, Dilley J, Yu J, Wu S, Chin SM, Lee NA, Rossi A, Lin JC, Rajpal A, Pons J, Shelton DL.

J Pharmacol Exp Ther. 2012 Feb;340(2):228-36. doi: 10.1124/jpet.111.187419. Epub 2011 Oct 21.

18.

Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation.

Seidah NG, Poirier S, Denis M, Parker R, Miao B, Mapelli C, Prat A, Wassef H, Davignon J, Hajjar KA, Mayer G.

PLoS One. 2012;7(7):e41865. doi: 10.1371/journal.pone.0041865. Epub 2012 Jul 27.

19.

Effects of lipoprotein apheresis on PCSK9 levels.

Julius U, Milton M, Stoellner D, Rader D, Gordon B, Polk D, Waldmann E, Parhofer KG, Moriarty PM.

Atheroscler Suppl. 2015 May;18:180-6. doi: 10.1016/j.atherosclerosissup.2015.02.028.

PMID:
25936324
20.

The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2.

Poirier S, Mayer G, Benjannet S, Bergeron E, Marcinkiewicz J, Nassoury N, Mayer H, Nimpf J, Prat A, Seidah NG.

J Biol Chem. 2008 Jan 25;283(4):2363-72. Epub 2007 Nov 26.

Supplemental Content

Support Center